Renal anemia treatment in chronic kidney disease patients

Renal anemia treatment in chronic kidney disease patients - Renal anemia treatment in chronic kidney disease patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021774

Enrollment

300

Registered

2016-04-04

Start date

2005-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia in chronic kidney disease patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic kidney disease patients with renal anemia that are required to treat by erythropoiesis-stimulating agents.

Exclusion criteria

Exclusion criteria: Patients complicated with potential diseases causing anemia such as hemorrhagic disease, hematological disease, or carcinoma.

Design outcomes

Primary

Measure	Time frame
To compare the incidence of CVEs and the survival rate during ESAs administration in three kinds of ESAs [epoetin(EPO), darbepoetin alpha(DPO), and epoetin beta pegol(EPObp)]	—

Secondary

Measure	Time frame
To compare the frequency of adverse events and degree of increase in hemoglobin (Hb) in three kinds of ESAs (EPO, DPO, and EPObp)	—

Countries

Japan

Contacts

Public ContactMichio Kuwahara

Shuuwa General Hospital Department of Nephrology

kuwaharam@shuuwa-gh.or.jp048-737-2121

Outcome results